Glycodeoxycholic acidCAS# 360-65-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 360-65-6 | SDF | Download SDF |
| PubChem ID | 3035026 | Appearance | Powder |
| Formula | C26H43NO5 | M.Wt | 449.63 |
| Type of Compound | Steroids | Storage | Desiccate at -20°C |
| Synonyms | Glycodeoxycholate | ||
| Solubility | DMSO : 250 mg/mL (556.03 mM; Need ultrasonic) | ||
| Chemical Name | 2-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid | ||
| SMILES | CC(CCC(=O)NCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C | ||
| Standard InChIKey | WVULKSPCQVQLCU-BUXLTGKBSA-N | ||
| Standard InChI | InChI=1S/C26H43NO5/c1-15(4-9-23(30)27-14-24(31)32)19-7-8-20-18-6-5-16-12-17(28)10-11-25(16,2)21(18)13-22(29)26(19,20)3/h15-22,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16-,17-,18+,19-,20+,21+,22+,25+,26-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Glycodeoxycholic acid levels could as prognostic biomarker in acetaminophen-induced acute liver failure patients. Glycodeoxycholic acid can induce the apoptosis of SMMC-7721 cells. |
| Targets | p53 |
| In vitro | The effect of glycodeoxycholic acid on P53 expression in the apoptosis of SMMC-7721 cells[Reference: WebLink]Chinese Journal of Clinical Laboratory Science, 2009, 27(3):167-169.To investigate the effect of Glycodeoxycholic acid(GDCA) on apoptosis of and P53 expression in SMMC-7721 cells. |
| In vivo | Glycodeoxycholic Acid Levels as Prognostic Biomarker in Acetaminophen-Induced Acute Liver Failure Patients[Pubmed: 25239633]Toxicol Sci. 2014 Dec; 142(2): 436–444.Acetaminophen (APAP)-induced acute liver failure (ALF) remains a major clinical problem. Although a majority of patients recovers after severe liver injury, a subpopulation of patients proceeds to ALF. Bile acids are generated in the liver and accumulate in blood during liver injury, and as such, have been proposed as biomarkers for liver injury and dysfunction. The goal of this study was to determine whether individual bile acid levels could determine outcome in patients with APAP-induced ALF (AALF).
|
Glycodeoxycholic acid Dilution Calculator
Glycodeoxycholic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2241 mL | 11.1203 mL | 22.2405 mL | 44.481 mL | 55.6013 mL |
| 5 mM | 0.4448 mL | 2.2241 mL | 4.4481 mL | 8.8962 mL | 11.1203 mL |
| 10 mM | 0.2224 mL | 1.112 mL | 2.2241 mL | 4.4481 mL | 5.5601 mL |
| 50 mM | 0.0445 mL | 0.2224 mL | 0.4448 mL | 0.8896 mL | 1.112 mL |
| 100 mM | 0.0222 mL | 0.1112 mL | 0.2224 mL | 0.4448 mL | 0.556 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- [Ala17]-MCH
Catalog No.:BCC6024
CAS No.:359784-84-2
- 3,6-Ditigloyloxynortropane
Catalog No.:BCN1877
CAS No.:359723-70-9
- Pterosin G
Catalog No.:BCN8148
CAS No.:35964-50-2
- Triptotin F
Catalog No.:BCN3482
CAS No.:359630-36-7
- Inotodiol
Catalog No.:BCN3331
CAS No.:35963-37-2
- 3-Acetoxy-11-ursen-28,13-olide
Catalog No.:BCN5313
CAS No.:35959-08-1
- 3-Hydroxy-11-ursen-28,13-olide
Catalog No.:BCN5312
CAS No.:35959-05-8
- Anchustrigosine
Catalog No.:BCC8185
CAS No.:
- Pteroside D
Catalog No.:BCN5311
CAS No.:35943-38-5
- Triciribine
Catalog No.:BCC3872
CAS No.:35943-35-2
- Pterosin C
Catalog No.:BCN7104
CAS No.:35938-43-3
- Vicenin -1
Catalog No.:BCN3012
CAS No.:35927-38-9
- Nandrolone decanoate
Catalog No.:BCC9087
CAS No.:360-70-3
- 2',4'-Dihydroxy-6'-methoxyacetophenone
Catalog No.:BCN5314
CAS No.:3602-54-8
- Ecdysone
Catalog No.:BCN2629
CAS No.:3604-87-3
- Diepiserratenediol
Catalog No.:BCN7433
CAS No.:3604-92-0
- Alpinetin
Catalog No.:BCN5315
CAS No.:36052-37-6
- Dihydrosanguinarine
Catalog No.:BCN3713
CAS No.:3606-45-9
- Tetrahydrocurcumin
Catalog No.:BCN2724
CAS No.:36062-04-1
- Hexahydrocurcumin
Catalog No.:BCN4641
CAS No.:36062-05-2
- Octahydrocurcumin
Catalog No.:BCN2725
CAS No.:36062-07-4
- B-HT 933 dihydrochloride
Catalog No.:BCC7474
CAS No.:36067-72-8
- B-HT 920
Catalog No.:BCC1417
CAS No.:36085-73-1
- Sodium cholate
Catalog No.:BCN6981
CAS No.:361-09-1
High expression of CCDC25 in cholangiocarcinoma tissue samples.[Pubmed:28789463]
Oncol Lett. 2017 Aug;14(2):2566-2572.
Cholangiocarcinoma (CCA) is a malignant transformation of biliary epithelial cells. It is a slow growing tumor, but is also highly metastatic with a poor prognosis. Bile acids are known to transactivate the epidermal growth factor receptor (EGFR) in cholangiocytes and induce cyclooxygenase-2 expression. The protein expression profiles of bile acid-treated CCA cells were studied using a proteomic approach. To elucidate the possible mechanisms involved in the bile acid-mediated enhancement of CCA cell migration, the effects of six bile acids, including cholic, deoxycholic, taurocholic, taurodeoxycholic, glycocholic and Glycodeoxycholic acid, on the migration of CCA cells were examined in vitro using wound healing assays. Subsequently, the possible proteins involved in enhanced CCA cell migration were investigated using a proteomic approach. Changes to the protein expression profiles of CCA cells following bile acid treatment was examined using two-dimensional electrophoresis and mass spectrometry. The results demonstrated that cholic and deoxycholic acid significantly enhanced the migration of CCA cells, compared with the treated MMNK-1 control cells. CCA cells had 77 overexpressed protein spots following cholic acid treatment, and 50 protein spots following deoxycholic acid treatment, compared with the treated MMNK-1 control cells. Liquid chromatography tandem-mass spectrometry analysis revealed that coiled-coil domain containing 25 (CCDC25) was significantly overexpressed in cholic acid-treated CCA cells compared with in cholic acid-treated control cells. When the expression levels of CCDC25 were investigated using western blot analysis, CCDC25 was demonstrated to be highly expressed in CCA tissues, but not in the adjacent non-cancerous tissue samples. The identified proteins were further analyzed for protein-chemical interactions using STITCH version 3.1 software. CCDC25 protein was identified to be associated with Son of sevenless homolog 1 and growth factor receptor-bound protein 2, which are involved in EGFR signaling. The results of the present study demonstrated that following cholic acid treatment, CCDC25 is overexpressed in CCA cells, which is associated with significantly enhanced cell migration. This suggests that CCDC25 is a potential therapeutic target for the treatment of patients with CCA.
Bile acid patterns in commercially available oxgall powders used for the evaluation of the bile tolerance ability of potential probiotics.[Pubmed:29494656]
PLoS One. 2018 Mar 1;13(3):e0192964.
This study aimed to analyze the bile acid patterns in commercially available oxgall powders used for evaluation of the bile tolerance ability of probiotic bacteria. Qxgall powders purchased from Sigma-Aldrich, Oxoid and BD Difco were dissolved in distilled water, and analyzed. Conjugated bile acids were profiled by ion-pair high-performance liquid chromatography (HPLC), free bile acids were detected as their p-bromophenacyl ester derivatives using reversed-phase HPLC after extraction with acetic ether, and total bile acids were analyzed by enzymatic-colorimetric assay. The results showed that 9 individual bile acids (i.e., taurocholic acid, glycocholic acid, taurodeoxycholic acid, Glycodeoxycholic acid, taurochenodeoxycholic acid, glycochenodeoxycholic acid, cholic acid, chenodeoxycholic acid, deoxycholic acid) were present in each of the oxgall powders tested. The content of total bile acid among the three oxgall powders was similar; however, the relative contents of the individual bile acids among these oxgall powders were significantly different (P < 0.001). The oxgall powder from Sigma-Aldrich was closer to human bile in the ratios of glycine-conjugated bile acids to taurine-conjugated bile acids, dihydroxy bile acids to trihydroxy bile acids, and free bile acids to conjugated bile acids than the other powders were. It was concluded that the oxgall powder from Sigma-Aldrich should be used instead of those from Oxoid and BD Difco to evaluate the bile tolerance ability of probiotic bacteria as human bile model.
Antimicrobial cholic acid derivatives from the Pitch Lake bacterium Bacillus amyloliquefaciens UWI-W23.[Pubmed:29702138]
Steroids. 2018 Jul;135:50-53.
Six cholic acid derivatives (1-6) were isolated from broth cultures of Bacillus amyloliquefaciens UWI-W23, an isolate from the Trinidad Pitch Lake. The compounds were extracted via solvent extraction and/or XAD resin adsorption and purified using silica gel column chromatography. Their structures were elucidated using 1D, 2D NMR and ESI-MS spectrometry and FT-IR spectrophotometry. One of the compounds, taurodeoxycholate (2) is for the first time being reported from a bacterial source while deoxycholate (4) is for the first time being reported from a Gram-positive bacterium. The other compounds have not been previously isolated from Bacillus spp. viz. cholate (1), taurocholic acid (3); Glycodeoxycholic acid (5) and glycocholic acid (6). All six compounds exhibited antimicrobial activity against P. aeruginosa and B. cereus with MICs ranging from 7 to 250microg/mL. Cholate (1) also showed activity against MRSA (MICs=125microg/mL) and glycocholic acid (6) against S. cerevisiae (MICs=15.6microg/mL).
